

New Treatment for Amyotrophic Lateral Sclerosis (ALS)

Published date: June 7, 2019

Technology description

Telbivudine to Abrogate Amyotrophic Lateral Sclerosis

Dr. Ted Allison and his team at the University of Alberta have discovered that telbivudine, a blood brain barrier-permeable thymidine analogue approved for treatment of Hepatitis B, is effective in ameliorating Amyotrophic Lateral Sclerosis (ALS). Results from in vitro studies have shown that telbivudine binds with tryptophan 32 residue in superoxide dismutase 1 (SOD1) gene and prevents SOD1 misfolding. In vivo studies in zebrafish models have shown that administration of telbivudine results in a significant improvement in motor neuron function and swim performance along with reduced toxicity effects in comparison to uridine and 5 Fluorouridine.

Institution

[University of Alberta](#)

联系我们



叶先生

电话：021-65679356

手机：13414935137

邮箱：yeyingsheng@zf-ym.com